Results

1–10 of 101 results for Pharmacology

Phase 2a Study of CU06-1004, an Oral Endothelial Dysfunction Blocker for the Treatment of Diabetic Macular Edema
Victor Hugo Gonzalez, MD
Updates from the Field
2024
Pegcetacoplan Safety: Panel Recap
Andre J. Witkin, MD
Updates from the Field
2024
Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept
Mark R. Barakat, MD
Annual Meeting Talks
2022
Noninferiority of 1.7% Povidone–Iodine for Endophthalmitis Prophylaxis After Intravitreal Injections Compared With 5% Povidone–Iodine in an Office Setting
Kamal Kishore, MD, MBBS
Annual Meeting Talks
2022
Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal Phase 3 MIRA Trials
David S. Boyer, MD
Annual Meeting Talks
2022
Surrobody: Novel Platform With Strong Therapeutic Characteristics and a Lead Candidate Molecule Bispecific RO-634 to VEGF and Ang-2
On Demand Cases, Courses, and Papers
2022
Biocompatibility and Affinity of RO-634, a Novel Bispecific Protein
On Demand Cases, Courses, and Papers
2022
Evaluating Pentosan Polysulfate Sodium-Associated Retinopathy Risk Factors and Grading Criteria
S. Krishna Mukkamala, MD, FASRS
Annual Meeting Talks
2021
Suprachoroidal Delivery of Small Molecule Suspensions: Pre-Clinical Results Correlate to Clinical Trial Outcomes
James C. Major, MD, PhD FACS FASRS
Annual Meeting Talks
2021
Efficacy and Safety of ‘Dropless Vitrectomy Surgery’ and Comparison of Outcomes to Standard of Care Topical Therapy
K. V. Chalam, MD, PhD, MBA, FRCS(C), FASRS
Annual Meeting Talks
2021